Pelthos Announces Merger with Castle Creek and $57.5 Million PIPE Financing

Filing content

Pelthos Therapeutics has entered into a definitive agreement to merge with Castle Creek Biosciences and secured $57.5 million in PIPE financing through the issuance of Series B convertible preferred stock and warrants, with the merger expected to close by the end of Q1 2027.